Evidence map›Paper›PMID 39860082›Full record

ArticleMolecules (Basel, Switzerland)2025

Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics.

Lorraine Gaenaelle Gé, Mathias Bogetoft Danielsen, Aaraby Yoheswaran Nielsen, Mathias Lander Skavenborg, Niels Langkjær, Helge Thisgaard, Christine J McKenzie

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Emerging Theranostic Radiometals (Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lorraine Gaenaelle GéDepartment of Nuclear Medicine, Odense University Hospital, Kloevervaenget 47, 5000 Odense C, Denmark.
Mathias Bogetoft DanielsenDepartment of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.
Aaraby Yoheswaran NielsenDepartment of Nuclear Medicine, Odense University Hospital, Kloevervaenget 47, 5000 Odense C, Denmark.ORCID 0000-0003-2199-2857
Mathias Lander SkavenborgDepartment of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.ORCID 0000-0003-2240-1692
Niels LangkjærDepartment of Nuclear Medicine, Odense University Hospital, Kloevervaenget 47, 5000 Odense C, Denmark.ORCID 0000-0002-8729-937X
Helge ThisgaardDepartment of Nuclear Medicine, Odense University Hospital, Kloevervaenget 47, 5000 Odense C, Denmark.ORCID 0000-0001-9492-448X
Christine J McKenzieDepartment of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.ORCID 0000-0001-5587-0626

Funding

Novo Nordisk Foundation NNF22OC0077099
6 · The paper itself

Abstract

The overexpression of the epidermal growth factor receptor (EGFR) in certain types of prostate cancers and glioblastoma makes it a promising target for targeted radioligand therapy. In this context, pairing an EGFR-targeting peptide with the emerging theranostic pair comprising the Auger electron emitter cobalt-58m (

Indexed as

Chelating AgentsCobaltPeptidesRadiopharmaceuticalsAnimalsCell Line, TumorErbB ReceptorsHumansMaleMicePositron-Emission TomographyTheranostic NanomedicineTissue DistributionChelating AgentsCobaltEGFR protein, humanErbB ReceptorsGE11 peptidePeptidesRadiopharmaceuticals57Co and 55Co)Co isotopes (58mCoEGFR targetingGE11polypyridyl chelatortheranostics

Identifiers

PMID39860082
PMCPMC11767697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.